{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:46:13Z","timestamp":1790621173508,"version":"4.1.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013348","name":"Innosuisse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013348","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAIM Foundation"},{"name":"GAMBIT Foundation"},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Society of Amyloidosis"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 HL 094301"],"award-info":[{"award-number":["T32 HL 094301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 HL 094301"],"award-info":[{"award-number":["T32 HL 094301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009269","name":"Amyloidosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Attralus, and Siemens"},{"DOI":"10.13039\/501100004362","name":"Swiss Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012654","name":"Olga Mayenfisch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012654","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Immanuel und Ilse Straub Stiftung"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac amyloidosis, characterized by the accumulation of misfolded proteins in the heart, is a major cause of restrictive cardiomyopathy. It includes two main forms\u2014transthyretin and immunoglobulin light chain amyloidosis\u2014and carries a poor prognosis if left untreated. With emerging new therapies, the growing need to assess treatment response highlights imaging biomarkers as valuable and promising surrogate endpoints. This review discusses current evidence on changes in imaging markers following treatment, contrasting them with the natural progression of the disease. The focus is on magnetic resonance and single photon emission tomography (SPECT) metrics, which have been found to detect treatment responses early, even before functional changes or clinical events occur, thus playing a key role in the management of cardiac amyloidosis. Once validated in larger studies with more data on reproducibility and linked to clinical outcomes, magnetic resonance and SPECT imaging markers could significantly improve disease monitoring and enable personalized care in cardiac amyloidosis. In an outlook to the future, the disruptive potential of amyloid binding positron emission tomography for evaluating amyloid load and treatment response is discussed.<\/jats:p>","DOI":"10.1093\/ehjci\/jeaf347","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:12:34Z","timestamp":1764853954000},"page":"452-466","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0798-6034","authenticated-orcid":false,"given":"Amely","family":"Walser","sequence":"first","affiliation":[{"name":"Cardiac Imaging, Department of Cardiology and Nuclear Medicine, University Hospital Zurich , R\u00e4mistrasse 100, Zurich CH-8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6029-0597","authenticated-orcid":false,"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, University Hospital Bern, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F","family":"St\u00e4mpfli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital , Lucerne ,","place":["Switzerland"]},{"name":"Center for Molecular Cardiology, University of Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A M","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier F","family":"Clerc","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardel J Romero","family":"Pab\u00f3n","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Vijayakumar","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat Itzhaki","family":"Ben Zadok","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-2033","authenticated-orcid":false,"given":"Rodney H","family":"Falk","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[{"name":"Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"CV Imaging Program, Cardiovascular Division, Department of Medicine and Radiology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-726X","authenticated-orcid":false,"given":"Dominik C","family":"Benz","sequence":"additional","affiliation":[{"name":"Cardiac Imaging, Department of Cardiology and Nuclear Medicine, University Hospital Zurich , R\u00e4mistrasse 100, Zurich CH-8091 ,","place":["Switzerland"]},{"name":"Advanced Clinician Scientist Program, University Medicine Zurich (UMZH), University of Zurich , R\u00e4mistrasse 71, Zurich CH-8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2026071701520405600_jeaf347-B1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026071701520405600_jeaf347-B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026071701520405600_jeaf347-B3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026071701520405600_jeaf347-B4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026071701520405600_jeaf347-B5","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","article-title":"Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases","volume":"44","author":"Benz","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071701520405600_jeaf347-B6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":":","key":"2026071701520405600_jeaf347-B7","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jcmg.2024.05.004","article-title":"Myocardial characteristics, cardiac structure, and cardiac function in systemic light-chain amyloidosis","volume":"17","author":"Clerc","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/ehjci\/jeaa329","article-title":"Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy\/Myocarditis Registry","volume":"22","author":"Mizia-Stec","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B10","doi-asserted-by":"crossref","first-page":"e017427","DOI":"10.1161\/CIRCIMAGING.124.017427","article-title":"MRI-extracellular volume fraction versus histological amyloid load in cardiac amyloidosis: the importance of T2 mapping","volume":"18","author":"Kidoh","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B11","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026071701520405600_jeaf347-B12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026071701520405600_jeaf347-B13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"key":"2026071701520405600_jeaf347-B16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026071701520405600_jeaf347-B17","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"issue":":","key":"2026071701520405600_jeaf347-B18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026071701520405600_jeaf347-B19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071701520405600_jeaf347-B20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026071701520405600_jeaf347-B21","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.amjcard.2017.07.025","article-title":"Functional cardiac recovery and hematologic response to chemotherapy in patients with light-chain amyloidosis (from the Stanford University Amyloidosis Registry)","volume":"120","author":"Tuzovic","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026071701520405600_jeaf347-B22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"43","author":"Cohen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026071701520405600_jeaf347-B24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026071701520405600_jeaf347-B25","doi-asserted-by":"crossref","first-page":"5049\u2013","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance","volume":"46","author":"Patel","year":"2025","journal-title":"Eur Heart J"},{"key":"2026071701520405600_jeaf347-B26","doi-asserted-by":"crossref","first-page":"e012135","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"issue":":","key":"2026071701520405600_jeaf347-B27","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/ehf2.14815","article-title":"Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy","volume":"11","author":"Dobner","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026071701520405600_jeaf347-B28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2026071701520405600_jeaf347-B30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/jcm13010284","article-title":"Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment","volume":"13","author":"Ney","year":"2024","journal-title":"J Clin Med"},{"key":"2026071701520405600_jeaf347-B32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13506129.2023.2247136","article-title":"Reduction in (99m)Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy","volume":"31","author":"Rettl","year":"2024","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-023-02824-0","article-title":"Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study","volume":"18","author":"Tsai","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026071701520405600_jeaf347-B34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13506129.2023.2284108","article-title":"Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy","volume":"31","author":"Dobner","year":"2024","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B35","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"key":"2026071701520405600_jeaf347-B36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3348\/kjr.2023.0985","article-title":"Light-chain cardiac amyloidosis: cardiac magnetic resonance for assessing response to chemotherapy","volume":"25","author":"Guo","year":"2024","journal-title":"Korean J Radiol"},{"key":"2026071701520405600_jeaf347-B37","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","article-title":"Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping","volume":"8","author":"Ioannou","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026071701520405600_jeaf347-B38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1532-429X-14-88","article-title":"Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR","volume":"14","author":"Fontana","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026071701520405600_jeaf347-B40","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071701520405600_jeaf347-B41","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","article-title":"Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells","volume":"7","author":"Imperlini","year":"2017","journal-title":"Sci Rep"},{"key":"2026071701520405600_jeaf347-B42","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026071701520405600_jeaf347-B43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99 m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"2026071701520405600_jeaf347-B44","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5 + 14) versus (18)F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":":","key":"2026071701520405600_jeaf347-B45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.semnuclmed.2024.05.012","article-title":"Radionuclide imaging of cardiac amyloidosis: an update and future aspects","volume":"54","author":"Clerc","year":"2024","journal-title":"Semin Nucl Med"},{"key":"2026071701520405600_jeaf347-B46","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative (99m)Tc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"2026071701520405600_jeaf347-B47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.semnuclmed.2024.02.005","article-title":"Artificial intelligence in nuclear cardiology: an update and future trends","volume":"54","author":"Miller","year":"2024","journal-title":"Semin Nucl Med"},{"key":"2026071701520405600_jeaf347-B48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","article-title":"Regression of myocardial (99m)Tc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"64","author":"Papathanasiou","year":"2023","journal-title":"J Nucl Med"},{"issue":":","key":"2026071701520405600_jeaf347-B49","first-page":"38","article-title":"Single-center analysis of cardiac amyloidosis using 99mTc-HMDP imaging for diagnosis and evaluation after tafamidis treatment","volume":"46","author":"Egi","year":"2024","journal-title":"Nucl Med Commun"},{"issue":":","key":"2026071701520405600_jeaf347-B50","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00259-025-07092-7","article-title":"Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy","volume":"52","author":"Ungericht","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026071701520405600_jeaf347-B51","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcmg.2022.12.016","article-title":"Tafamidis treatment decreases (99m)Tc-pyrophosphate uptake in patients with hereditary Ala97Ser transthyretin amyloid cardiomyopathy","volume":"16","author":"Yu","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026071701520405600_jeaf347-B53","first-page":"216","article-title":"A novel quantitative method for assessing the therapeutic response to tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report","volume":"25","author":"Doumas","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"2026071701520405600_jeaf347-B54","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jcmg.2022.06.013","article-title":"Tafamidis decreases cardiac uptake of (99m)Tc-HMDP in transthyretin cardiac amyloidosis","volume":"15","author":"Odouard","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-023-06459-y","article-title":"Cardiac [(99m)Tc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?","volume":"51","author":"Tingen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026071701520405600_jeaf347-B56","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B57","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.nuclcard.2024.102056","article-title":"SPECT\/CT quantification of 99m-TC PYP uptake to assess tafamidis treatment response in ATTR cardiac amyloidosis","volume":"42","author":"Godoy-Rivas","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"2026071701520405600_jeaf347-B58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.108.054205","article-title":"18F-FDG PET and PET\/CT in the evaluation of cancer treatment response","volume":"50","author":"Ben-Haim","year":"2009","journal-title":"J Nucl Med"},{"key":"2026071701520405600_jeaf347-B60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/13506129.2022.2120388","article-title":"Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging","volume":"30","author":"Oguchi","year":"2023","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2023.2286427","article-title":"Longitudinal PET\/CT imaging with iodine ((124)I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis","volume":"31","author":"Lands","year":"2024","journal-title":"Amyloid"},{"key":"2026071701520405600_jeaf347-B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.101800","article-title":"Feasibility of (11)C-Pittsburgh compound B positron emission tomography\/computed tomography for treatment monitoring with tafamidis in a patient with transthyretin cardiac amyloidosis","author":"Fujioka","year":"2024","journal-title":"J Nucl Cardiol"},{"issue":":","key":"2026071701520405600_jeaf347-B63","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jcmg.2025.07.017","article-title":"Changes in myocardial light chain amyloid burden after plasma cell therapy","volume":"18","author":"Benz","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071701520405600_jeaf347-B64","first-page":"221","article-title":"The role of artificial intelligence in cardiac amyloidosis: a focus on diagnosis and clinical application","volume":"12","author":"Wardak","year":"2025","journal-title":"J Cardiovasc Dev Dis"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jeaf347\/65806713\/jeaf347.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/3\/452\/65806713\/jeaf347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/3\/452\/65806713\/jeaf347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:52:15Z","timestamp":1784267535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/27\/3\/452\/8374376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,8]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeaf347","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,8]]}}}